{"filing":{"accession_number":"0001437749-26-022087","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"mbrx20260629_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926022087/mbrx20260629_8k.htm"},"events":[{"id":14869,"run_id":13254,"accession_number":"0001437749-26-022087","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The Company reports exercise of warrants to purchase 1,361,500 shares for approximately $2.7 million in gross proceeds, resulting in approximately 19% dilution to existing shareholders and a material increase in share count.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12440,"accession_number":"0001437749-26-022087","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports exercise of warrants to purchase 1,361,500 shares for approximately $2.7 million in gross proceeds, resulting in dilution to existing shareholders. While warrant exercises are technically different from unregistered equity issuances, they represent a dilutive capital event that increases share count and raises cash—the core concern of the dilutive_issuance category. The materiality is supported by the significant share count increase (roughly 19% dilution relative to the 7,065,000 shares outstanding post-exercise) and the material cash proceeds.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:30:46.562367+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":14870,"run_id":13254,"accession_number":"0001437749-26-022087","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"summary":"The Company furnished a corporate presentation to its website under Regulation FD, representing routine disclosure of investor relations materials.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12439,"accession_number":"0001437749-26-022087","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This is a Regulation FD disclosure of a corporate presentation posted to the Company's website. The filing explicitly states the information is being \"furnished\" under Item 7.01 and is not \"filed\" under the Exchange Act, indicating routine disclosure of investor relations materials rather than a material event. Without substantive content from the presentation itself, this appears to be administrative disclosure of corporate communications.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:30:46.562367+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12439,"accession_number":"0001437749-26-022087","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This is a Regulation FD disclosure of a corporate presentation posted to the Company's website. The filing explicitly states the information is being \"furnished\" under Item 7.01 and is not \"filed\" under the Exchange Act, indicating routine disclosure of investor relations materials rather than a material event. Without substantive content from the presentation itself, this appears to be administrative disclosure of corporate communications.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:30:46.562367+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-06-30"},{"id":12440,"accession_number":"0001437749-26-022087","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports exercise of warrants to purchase 1,361,500 shares for approximately $2.7 million in gross proceeds, resulting in dilution to existing shareholders. While warrant exercises are technically different from unregistered equity issuances, they represent a dilutive capital event that increases share count and raises cash—the core concern of the dilutive_issuance category. The materiality is supported by the significant share count increase (roughly 19% dilution relative to the 7,065,000 shares outstanding post-exercise) and the material cash proceeds.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:30:46.562367+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-06-30"}]}